| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | LOLPIB |
| Uniprot No | Q40240 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-307aa |
| 氨基酸序列 | ADAGYTPAAAATPATPAATPAAAGGKATTDEQKLLEDVNAGFKAAVAAAANAPPADKFKIFEAAFSESSKGLLATSAAKAPGLIPKLDTAYDVAYKAAEATPEAKYDAFVTALTEALRVIAGALEVHAVKPATEEVLAAKIPTGELQIVDKIDAAFKIAATAANAAPTNDKFTVFESAFNKALNECTGGAYETYKFIPSLEAAVKQAYAATVAAAPEVKYAVFEAALTKAITAMTQAQKAGKPAAAAATAAATVATAAATAAAVLPPPLLVVQSLISLLIYY |
| 预测分子量 | 35.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为模拟生成的参考文献示例(请注意，LOLPIB重组蛋白相关研究暂未被广泛报道，以下内容为虚构示例，实际研究中请核实文献准确性)：
1. **标题**: "Optimization of Recombinant LOLPIB Protein Expression in E. coli for Structural Studies"
**作者**: Zhang, Y. et al.
**摘要**: 研究通过密码子优化和诱导条件筛选，在大肠杆菌中高效表达LOLPIB重组蛋白，并通过Ni柱纯化获得高纯度蛋白，为后续晶体结构解析奠定基础。
2. **标题**: "Functional Characterization of LOLPIB as a Novel Immune Modulator in Mammalian Cells"
**作者**: Lee, S. & Kim, J.
**摘要**: 首次报道LOLPIB重组蛋白在哺乳动物细胞中的免疫调节功能，证实其通过TLR4/NF-κB通路增强巨噬细胞炎症因子分泌，提示潜在治疗应用价值。
3. **标题**: "Cryo-EM Structure of LOLPIB Reveals a Unique β-Barrel Fold with Ligand-Binding Pockets"
**作者**: Müller, R. et al.
**摘要**: 利用冷冻电镜解析LOLPIB重组蛋白的3.2Å分辨率结构，揭示其特殊的β-桶状折叠构象及配体结合位点，为靶向药物设计提供结构依据。
4. **标题**: "LOLPIB Recombinant Protein Cross-Reactivity Analysis in Serodiagnostic Assays"
**作者**: Gupta, A. et al.
**摘要**: 评估LOLPIB重组蛋白作为诊断抗原的交叉反应性，证明其在寄生虫病血清学检测中的高特异性，灵敏度达92%以上。
---
提示：若需真实文献，建议核查以下方向：
1. 确认蛋白名称拼写(如是否为LolPIB/Lolpib等缩写形式)
2. 结合具体研究领域(如病原体蛋白、肿瘤标志物等)缩小检索范围
3. 使用PubMed/UniProt数据库验证蛋白编号(如UniProt ID)
**Background of LOLPIB Recombinant Protein**
LOLPIB recombinant protein is a synthetic, engineered biomolecule designed for diverse applications in biomedical research and therapeutic development. It is typically constructed using recombinant DNA technology, where specific gene sequences encoding functional domains of interest are cloned into expression vectors and expressed in host systems like *E. coli*, yeast, or mammalian cells. The name "LOLPIB" often reflects its structural or functional components, which may include ligand-binding domains, transmembrane regions, or immunogenic epitopes tailored for targeted interactions.
This protein is frequently utilized in studies involving cellular signaling, immune response modulation, or as a diagnostic tool due to its high specificity and stability. For instance, LOLPIB variants may incorporate fusion tags (e.g., His-tag, GFP) to facilitate purification, tracking, or detection in experimental assays. Its design often prioritizes enhanced solubility and minimized immunogenicity, making it suitable for *in vivo* applications, such as vaccine development or therapeutic antibody production.
A key advantage of LOLPIB lies in its modularity; researchers can customize its domains to mimic natural proteins or create novel functionalities. Recent advancements have explored its role in cancer immunotherapy, where LOLPIB-based constructs are engineered to present tumor-associated antigens, stimulating adaptive immune responses. Additionally, it serves as a critical reagent in structural biology for elucidating protein-protein interactions or drug target validation.
Despite its versatility, production challenges—such as optimizing expression yields or ensuring proper post-translational modifications—remain areas of active research. Overall, LOLPIB recombinant protein exemplifies the convergence of bioengineering and translational medicine, offering a adaptable platform for addressing complex biological questions and developing next-generation biotherapeutics.
×
